The anti-inflammatory agent, started within 24 hours of acute ischemic stroke or TIA, did not reduce subsequent stroke or other vascular events at 90 days in the CHANCE-3 trial.
While the new drug reduced hematoma expansion compared with usual care, it was also associated with an increase in thrombotic events in the ANNEXa-I study.
Two new studies of the potential neuroprotective agent nerinetide for patients with acute ischemic stroke have shown conflicting results, with suggestions of benefit when given very early in the prehospital setting.
It s all exploratory, but asundexian given with antiplatelets showed safe nuanced potential against poststroke recurrent events and quashed circulating factor XIa after stenting for acute MI.